Regulation of glycogen metabolism by anti-dyslipidemic action of gemfibrozil and cholestyramine in a dyslipidemic-diabetic hamster model
| Autor: | Mohd Mubin Khan, Anju Puri, Ashok Kumar Khanna, Rashmi Saxena, Jitendra Kumar Saxena, Ramesh Chander |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cholestyramine biology medicine.drug_class Glucokinase Chemistry Organic Chemistry medicine.disease Glycogen debranching enzyme Glycogen phosphorylase Endocrinology Insulin resistance Bile acid sequestrant Internal medicine medicine biology.protein Gemfibrozil General Pharmacology Toxicology and Pharmaceutics Glycogen synthase medicine.drug |
| Zdroj: | Medicinal Chemistry Research. 17:245-257 |
| ISSN: | 1554-8120 1054-2523 |
| DOI: | 10.1007/s00044-007-9058-z |
| Popis: | Dyslipidemia with diabetes in hamsters, as a result of feeding with high-fat diet, caused accumulation of nonesterified fatty acid, increased lipolysis, and hyperglycemia, with decreased insulin activity. The lipid-lowering drug gemfibrozil improved insulin secretion and lowered the plasma glucose, plasma and tissue lipids viz., cholesterol, triglyceride, nonesterified fatty acids, and glycerol. Cholestyramine, a potent bile acid sequestrant was less effective than gemfibrozil in the diabetic-dyslipidemic hamster model. Treatment with the above drugs also affected glycogen metabolism by reactivation of the enzymes glycogen synthase, glucokinase, hexokinase, and glycogen phosphorylase, in liver and muscle, and reduced fat load by increasing faecal excretion of lipids. These drugs counteracted the insulin resistance by improving insulin secretion. Gemfibrozil was more effective than cholestyramine in controlling hyperglycemia, because the lipid-lowering action of the latter was mediated only by its bile acid sequestration activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink